Cargando…

TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action

Cancer immunotherapy has produced impressive clinical results in recent years. Despite the success of the checkpoint blockade strategies targeting cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death receptor 1 (PD-1), a large portion of cancer patients have not yet benefited from this nov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Wenwen, Yang, Min, Turner, Abbey, Xu, Chunling, Ferris, Robert L., Huang, Jianan, Kane, Lawrence P., Lu, Binfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372657/ https://www.ncbi.nlm.nih.gov/pubmed/28300768 http://dx.doi.org/10.3390/ijms18030645

Ejemplares similares

Mast cell activation is enhanced by Tim1:Tim4 interaction but not by Tim-1 antibodies
por: Phong, Binh, et al.
Publicado: (2016)

Immune regulation by Tim-3
por: Banerjee, Hridesh, et al.
Publicado: (2018)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

TIM-3, a promising target for cancer immunotherapy
por: He, Yayi, et al.
Publicado: (2018)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

New emerging targets in cancer immunotherapy: the role of TIM3
por: Friedlaender, Alex, et al.
Publicado: (2019)

TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy
por: Dayoub, Adam S., et al.
Publicado: (2020)

The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?
por: Ganjalikhani Hakemi, Mazdak, et al.
Publicado: (2020)

Murine Tim-1 is excluded from the immunological synapse
por: Lin, Jean, et al.
Publicado: (2012)

A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy
por: Kuang, Zhihui, et al.
Publicado: (2020)

TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors
por: Sauer, Natalia, et al.
Publicado: (2023)

B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
por: Tian, Xinyu, et al.
Publicado: (2023)

TIM-3(+) T cells are not exhausted but activated cells in the tumor microenvironment
por: Jie, Hyun-Bae, et al.
Publicado: (2013)

Tim-3 finds its place in the cancer immunotherapy landscape
por: Acharya, Nandini, et al.
Publicado: (2020)

TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression
por: Gao, Xin, et al.
Publicado: (2012)

Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment
por: Banerjee, Hridesh, et al.
Publicado: (2021)

TIM-3 as a Prognostic Marker and a Potential Immunotherapy Target in Human Malignant Tumors: A Meta-Analysis and Bioinformatics Validation
por: Zang, Kui, et al.
Publicado: (2021)

The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer
por: Kozłowski, Mateusz, et al.
Publicado: (2022)

Differential expression of PD-1 and Tim-3 marks activation versus exhaustion status of T cells in the tumor microenvironment
por: Li, Jing, et al.
Publicado: (2014)

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
por: Yang, Riyao, et al.
Publicado: (2021)

PD-1 blockade upregulate TIM-3 expression as a compensatory regulation of immune check point receptors in HNSCC TIL
por: Shayan, Gulidanna, et al.
Publicado: (2015)

The structure of Tim50(164–361) suggests the mechanism by which Tim50 receives mitochondrial presequences
por: Li, Jingzhi, et al.
Publicado: (2015)

Mertk Interacts with Tim-4 to Enhance Tim-4-Mediated Efferocytosis
por: Moon, Byeongjin, et al.
Publicado: (2020)

Tim Burton /
por: Marcos Arza, Marcos
Publicado: (2007)

Tim Lou
por: Lou, Hou Keong
Publicado: (2009)

The Small Toxic Salmonella Protein TimP Targets the Cytoplasmic Membrane and Is Repressed by the Small RNA TimR
por: Andresen, Liis, et al.
Publicado: (2020)

Tim1 and Tim3 are not essential for experimental allergic asthma
por: Barlow, J L, et al.
Publicado: (2011)

Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor
por: Schwartz, Stephanie, et al.
Publicado: (2022)

Mitochondrial Tim9 protects Tim10 from degradation by the protease Yme1
por: Spiller, Michael P., et al.
Publicado: (2015)

Identification of TIM3 2′-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy
por: Hervas-Stubbs, Sandra, et al.
Publicado: (2015)

Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways
por: Zhu, Zhi, et al.
Publicado: (2022)

TIM-Finder: A new method for identifying TIM-barrel proteins
por: Si, Jing-Na, et al.
Publicado: (2009)

Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activation
por: Phong, Binh L., et al.
Publicado: (2015)

Altered expression of Tim family molecules and an imbalanced ratio of Tim-3 to Tim-1 expression in patients with type 1 diabetes
por: Liu, Yikai, et al.
Publicado: (2022)

Interview with Tim Smith
por: Smith, Tim, et al.
Publicado: (2019)

Tim Berners-Lee
Publicado: (2004)

Come on, Sir Tim!
Publicado: (2009)

Tim-3 mediates T cell trogocytosis to limit antitumor immunity
por: Pagliano, Ornella, et al.
Publicado: (2022)

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
por: Marcq, Elly, et al.
Publicado: (2017)

The Tim54p–Tim22p Complex Mediates Insertion of Proteins into the Mitochondrial Inner Membrane
por: Kerscher, Oliver, et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_kkjeg51vijarmdjcdvo0ml6771